The results of a phase 3 trial involving 1,140 patients have been published in the New England Journal of Medicine.
ONCOLOGY
Fully funded by 
Content independently selected
-
-
ESMO 2019 — Advanced ovarian cancer: adding olaparib to bevacizumab prolongs progression-free survival An interim data analysis.
-
ESMO 2019 — Trametinib tackles chemoresistance in recurrent/progressive low-grade serous ovarian or peritoneal cancer Possibly a new standard of care for these carcinomas.
-
ESMO 2019 — Niraparib effective in newly diagnosed advanced ovarian cancer Should first-line platinum-based chemotherapy be followed by the PARP inhibitor niraparib in advanced ovarian cancer?
-
ESMO 2019 — Overview of Presidential Symposium I: ovarian and lung cancer Beyond BRCA in ovarian cancer?
-
ESMO 2019 — Combination of cediranib and olaparib has clinical benefit in BRCA wild-type platinum-resistant ovarian cancer Small study shows encouraging results in heavily pretreated patients.
-
Recurrent ovarian cancer: extending platinum-free interval yields poorer survival Study evaluates effect of nonplatinum chemotherapy, targeted therapy.
-
Advanced ovarian cancer: maintenance pazopanib fails phase 3 trial No OS benefit in final analysis.
-
UK cancer survival still lags behind other countries An examination of survival rates for seven tumour types in seven different jurisdictions
-
Adding bevacizumab to niraparib extends PFS in recurrent ovarian cancer Phase 2 data show benefit regardless of HRD status, chemotherapy-free interval.
-
NACT+interval cytoreduction extends survival in geriatric ovarian cancer Use of NACT+ICS increased during study period.
-
The test that may be able to detect epithelial ovarian cancer up to two years earlier than current approaches.
-
Ovarian cancer: immunotherapy may boost survival benefit of later chemotherapy Survival benefit was independent of response to checkpoint inhibitors.
-
Nintedanib fails to boost survival in advanced ovarian cancer Phase 3 trial shows no benefit with standard frontline chemotherapy.